Healthcare Services

Gonorrhea Therapeutics Market Revenue Growth Expected to Reach $2.51 Billion by 2030 with 4.9% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Gonorrhea Therapeutics Market Evolve From 2026 To 2030?

The gonorrhea therapeutics market size has shown significant expansion in recent years. This market is expected to increase from $1.97 billion in 2025 to $2.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.2%. The historical growth experienced by this market can be attributed to factors such as global STI prevalence, antibiotic availability, public health interventions, hospital infection treatment protocols, and diagnostic laboratory expansion.

The gonorrhea therapeutics market size is anticipated to experience consistent growth in the coming years. It is projected to expand to $2.52 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.9%. This expansion during the forecast period is attributed to drug innovation prompted by resistance, an uptick in sexual health screening, public health funding, the development of novel antibiotics, and telehealth services for STI management. Significant trends for the forecast period include heightened monitoring of antibiotic resistance, an increased reliance on combination antibiotic therapy, the extension of STI screening programs, the proliferation of public health awareness campaigns, and wider adoption of enhanced diagnostic testing.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21195&type=smp

What Drivers Are Influencing The Gonorrhea Therapeutics Market?

The rising incidence of sexually transmitted infections is projected to stimulate the expansion of the gonorrhea therapeutics market in the future. A sexually transmitted infection (STI) is an ailment transmitted via sexual contact, caused by bacteria, viruses, or parasites. The increase in these infections stems from factors such as unprotected sex, insufficient awareness or education, a higher number of sexual partners, decreased use of condoms, and delayed or inadequate testing and treatment. Gonorrhea therapeutics are utilized to address sexually transmitted infections by targeting the Neisseria gonorrhoeae bacteria, thereby preventing associated complications and transmission. For example, a June 2024 report from the National Institute for Public Health and the Environment, a government agency in the Netherlands, highlighted a significant year-over-year rise in gonorrhea cases diagnosed at SHCs, increasing from 10,600 in 2022 to 13,853 in 2023, which represents a 31% growth. Hence, the escalating occurrence of sexually transmitted infections is propelling the growth of the gonorrhea therapeutics market.

Which Segment Areas Are Covered In The Gonorrhea Therapeutics Market Analysis?

The gonorrhea therapeutics market covered in this report is segmented –

1) By Therapeutic Class: Antibiotics, Combination Therapy

2) By Route Of Administration: Oral, Intravenous, Intramuscular

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Clinics, Home Care

Subsegments:

1) By Antibiotics: Beta-lactams, Macrolides, Fluoroquinolones, Aminoglycosides

2) By Combination Therapy: Dual Antibiotic Therapy, Triple Antibiotic Therapy

What Trends Are Advancing Progress In The Gonorrhea Therapeutics Market?

Major companies operating in the gonorrhea therapeutics market are developing innovative products, such as quick polymerase chain reaction (PCR) tests, to facilitate swift, accurate detection of pathogens and their characteristics, including antibiotic resistance, directly at the point of care. A quick polymerase chain reaction (PCR) test is a diagnostic method designed to rapidly amplify and pinpoint specific DNA or RNA sequences, thereby enabling fast identification of pathogens or genetic material. For example, in February 2024, Visby Medical, Inc., a US-based medical technology company, launched a gonorrhea test that incorporates an antimicrobial resistance check. This rapid diagnostic test is crafted to identify the presence of Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, and to assess its susceptibility to ciprofloxacin, an antibiotic against which some gonorrhea strains have developed resistance. The test is integrated into a portable, instrument-free PCR platform, allowing for immediate screening at the patient’s location. It was developed with financial support from the US non-profit organization CARB-X, and the company intends to expand the test to include the detection of other sexually transmitted infections in men, such as Chlamydia trachomatis and Trichomonas vaginalis.

Which Global Companies Are Actively Competing In The Gonorrhea Therapeutics Market?

Major companies operating in the gonorrhea therapeutics market are Pfizer Inc., F Hoffmann La Roche Ltd, GlaxoSmithKline plc, Aurobindo Pharma Limited, Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Summit Therapeutics Inc., Merck Co Inc, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi S A, Bayer AG, Nobelex Biotech, Evofem Biosciences Inc., NextGen Pharma

Read the full gonorrhea therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/gonorrhea-therapeutics-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Gonorrhea Therapeutics Market?

North America was the largest region in the gonorrhea therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gonorrhea therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gonorrhea Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21195&type=smp

Browse Through More Reports Similar to the Global Gonorrhea Therapeutics Market 2026, By The Business Research Company

Hormone Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Human Chorionic Gonadotropin Global Market Report

https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report

Follicle Stimulating Hormone Global Market Report

https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795